Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Is hormone therapy tied to lower brain SVD?
Investigators found greater white matter integrity among older women who reported menopausal hormone therapy use, while associations with reproductive lifespan and oral contraceptives were less consistent.
To examine associations between reproductive history and hormone therapy use and brain small vessel disease (SVD), white matter integrity, and Alzheimer’s disease–related imaging and cerebrospinal fluid measures in older women.
Approach:
Participants: Researchers studied 352 cognitively unimpaired women in Sweden’s Gothenburg H70-1944 Birth Cohort; 205 had repeat brain MRI about five years later.
Exposures and measures: They assessed reproductive lifespan and self-reported oral contraceptive and menopausal hormone therapy use. MRI measures included an SVD score and white matter fractional anisotropy; analyses also examined cortical thickness, cerebrospinal fluid biomarkers, A…
Analysis: Regression models adjusted for education and relevant reproductive or cardiometabolic factors. The investigators also corrected for multiple comparisons.
Key Findings:
MHT use was associated with 59% lower odds of having at least two SVD markers and with greater white matter integrity; both associations remained significant after multiple-comparison correction.
Each additional year of reproductive lifespan was associated with 8% lower odds of at least two SVD markers, with later menopause accounting for the association in further analyses. This finding did not remain significant after correction.
Associations between MHT and lower odds of cerebral microbleeds or enlarged perivascular spaces did not remain significant after correction. The oral-contraceptive association with white matter integrity also did not remain significant.
There were no significant overall associations with Alzheimer’s disease–related cortical thickness or abnormal cerebrospinal fluid biomarkers. An association between MHT and greater cortical thickness among APOE ε4 carriers did not remain significant after cor…
Over about five years, reproductive lifespan and hormone therapy use were not significantly associated with changes in cortical thickness or white matter hyperintensity volume.
Interpretation:
The authors stated that the results contribute to mechanistic understanding rather than immediate clinical translation.
Limitations:
The observational design cannot establish causality or determine whether imaging differences translate into cognitive benefits.
Hormone histories were retrospectively self-reported, and information on treatment formulation, dose, route, duration, and timing was limited.
The longitudinal imaging sample was small, and follow-up attrition may have introduced selection bias or reduced the ability to detect associations.
The cohort comprised cognitively unimpaired older Swedish women, which may limit generalizability.
Adults assigned to nonnutritive sweetened beverages or water maintained weight reductions through 104 weeks, with no statistically significant difference between groups.
A large BRFSS analysis points to persistent screening disparities among sexual orientation and gender identity minority respondents, with particularly large gaps in some gender identity minority groups.